IN BRIEF: Physiomics wins first contract from Numab Therapeutics

Tue, 11th May 2021 17:50

Physiomics PLC - oncology consultant based in Oxford - Awarded its first contract by Zurich-based biopharmaceutical company Numab Therapeutics, which is focused on developing biotherapeutics for chronic inflammation and cancer.

"We are delighted that Numab has selected Physiomics to support them with one of their new programs and look forward to working with their highly talented team," notes Chief Executive Officer Jim Millen.

Current stock price: 5.91 pence

Year-to-date change: down 20%

By Dayo Laniyan; dayolaniyan@alliancenews.com

Related Shares

More News

3 May 2024 14:34

IN BRIEF: Physiomics warns large contracts taken longer than expected

Physiomics PLC - Milton Park, England-based data science company, focused on new therapeutics and personalised medicine solutions - Warns several larg...

3 May 2024 11:21

Physiomics lowers forecasts amid contract delays

(Sharecast News) - Therapeutics and medicine-focussed mathematical modelling and data science company Physiomics said in an update on Friday that, des...

3 May 2024 10:52

AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

18 Mar 2024 11:57

IN BRIEF: Physiomics celebrates "substantial" contract with old client

Physiomics PLC - mathematical modelling company that supports oncology drug development - Receives a "substantial" new contract by an existing "large ...

18 Mar 2024 09:43

Physiomics secures 'substantial new contract' with existing pharma client

(Sharecast News) - Mathematical modelling and data science company Physiomics has been awarded "a substantial new contract" by an existing large pharm...